Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD Clinical Trial of GM-2505
Gilgamesh Pharmaceuticals, a clinical-stage neuroscience biotech developing best-in-class medicines to redefine mental healthcare, announces the successful completion of its Phase 1 Single Ascending Dose (SAD) trial of GM-2505, a novel 5-HT2A receptor agonist. While initially in development for treatment-resistant depression…
Pharmactive Biotech Products Joins the B Corp Community
Pharmactive Biotech Products, SLU, a pioneer in the research and development of high-quality natural extracts, announces its establishment as a certified B Corporation. This designation reaffirms the company’s dedication to upholding high standards in terms of social and environmental performance,…
Glassbeam Awarded FedRAMP® ‘In-Process’ Status for its SaaS analytics solution for connected medical systems
Glassbeam, Inc., a pioneer in data and predictive analytics for connected medical machines, today announced it has achieved the ‘In Process’ milestone as a Cloud Service Provider for listing on the FedRAMP® marketplace for their Clinsights solutions. FedRAMP is the U.S….
Viriom’s Single Pill Influenza Treatment Completes Critical Phase I Clinical Trials
Viriom Inc., dedicated to advancing a pipeline of highly effective and broadly affordable treatments targeting infectious and malignant diseases globally, announces the successful completion and positive results of Phase I clinical trial for AV5124, a novel inhibitor of influenza virus…
Alo Expands Avance Care Presence with Addition of Durham Family Medicine
Alo, the North Carolina-based healthcare company founded to support independent providers and help them maintain their independence, is continuing its growth by adding Durham Family Medicine to its lineup of primary care practices operating under the Avance Care banner. The addition…
Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective in ACcomplisH China Phase 2 Trial
VISEN Pharmaceuticals (VISEN), an innovative biopharmaceutical company focused on endocrine diseases, is pleased to announce the topline results from the ACcomplisH China Phase 2 Trial in children with achondroplasia (ACH) aged 2 to 10 years. In the trial, patients dosed…
Together Senior Health Partners with Leading ACO Rainier Health Network, an Affiliate of CommonSpirit, to Bring Dementia-Specific Care Programs to Dementia Patients
Together Senior Health, a brain health company delivering evidence-based solutions for individuals with Alzheimer’s Disease and Related Dementias (ADRD), today announced a new strategic partnership with Rainier Health Network, a prominent Accountable Care Organization (ACO) overseeing the healthcare of over 60,000…
Ocutrx Unveils OcuLenz AR/XR Headset, Aiding Vision for Patients with Advanced Macular Degeneration
Ocutrx Technologies, Inc., a leader in augmented reality (AR) and 3D technology for medical and surgical applications, today is pulling back the curtain on its latest innovation: OcuLenz™, its groundbreaking AR/XR headset. OcuLenz is engineered to enhance visual clarity for individuals…
Bio-Botanica® announces Puresterol® (pueraria mirifica) based serums found to reduce wrinkles in clinical trials
Bio-Botanica, Inc., ® the one American company that has manufactured botanical extracts under one family for more than 50 years, has revealed the results of clinical trials indicating its proprietary botanical extract ingredient, Puresterol® (Pueraria mirifica), showed positive effects on the reduction of…
Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the U.S. Food and Drug Administration (FDA) has approved Recor’s Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension. The Paradise…
